ValiRx Plc logo

ValiRx Plc (EAJF)

Market Open
22 Oct, 06:02 AM
XFRA XFRA
€
0. 00
0
0%
€
- Market Cap
- P/E Ratio
- Div Yield
30,000 Volume
- Eps
€ 0
Previous Close
Add Transaction
Day Range
0 0
Year Range
0 0.02
Want to track EAJF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

EAJF trading today higher at €0, an increase of 0% from yesterday's close, completing a monthly increase of 0% or €0. Over the past 12 months, EAJF stock gained 0%.
EAJF is not paying dividends to its shareholders.
The last earnings report, released on Sep 25, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
ValiRx Plc has completed 2 stock splits, with the recent split occurring on Apr 06, 2020.
The company's stock is traded on one exchange.

EAJF Chart

ValiRx Plc (EAJF) FAQ

What is the stock price today?

The current price is €0.00.

On which exchange is it traded?

ValiRx Plc is listed on XFRA.

What is its stock symbol?

The ticker symbol is EAJF.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has ValiRx Plc ever had a stock split?

ValiRx Plc had 2 splits and the recent split was on Apr 06, 2020.

ValiRx Plc Profile

Biotechnology Industry
Healthcare Sector
Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D. CEO
XFRA Exchange
GB00BLH13C52 ISIN
United Kingdom Country
16 Employees
- Last Dividend
6 Apr 2020 Last Split
- IPO Date

Overview

ValiRx plc is a biopharmaceutical company based in England, United Kingdom, focused on the development of therapeutic products and companion diagnostics for cancer treatment. Founded in 2000, the company has been dedicated to creating innovative solutions for oncology, specifically targeting prostate cancer, non-small cell lung cancer, and endometriosis, along with developing treatments for severe symptoms of Covid-19. With a commitment to advancing healthcare through research, ValiRx combines scientific expertise with a passion for improving patient outcomes.

Products and Services

  • VAL201
  • A short peptide that targets prostate cancer, VAL201 has successfully completed Phase I/II clinical trials. It represents the company's dedication to combatting one of the most common types of cancer affecting men, showcasing ValiRx's forward-thinking approach to oncology.

  • VAL401
  • A reformulated version of the anti-psychotic drug risperidone, VAL401 has completed a Phase II clinical trial for treating end-stage non-small cell lung cancer. This innovative application reflects the company’s strategy of repurposing existing drugs to provide new cancer therapies.

  • VAL301
  • In pre-clinical development, VAL301 is a peptide ingredient aimed at treating endometriosis. This effort to tackle a painful and often debilitating condition that affects millions of women worldwide underscores ValiRx’s commitment to addressing a broad spectrum of unmet medical needs.

  • BC201
  • This combination of the peptide ingredient of VAL201/VAL301 with complementary active components is being developed for the treatment of patients suffering from severe symptoms of Covid-19. BC201 exemplifies the company’s agility in responding to global health crises by leveraging its existing technology portfolio.

  • CLX001
  • A peptide nanoparticle formulation in pre-clinical trial stages, CLX001 is designed for the destruction of cancer cells. This innovative approach to oncology treatment signals ValiRx's continual pursuit of novel and effective solutions in the fight against cancer.

Contact Information

Address: Stonebridge House
Phone: 44 24 7679 6496